Targeting PD-1/PD-L1 interactions for cancer immunotherapy

被引：293
|
作者：
Zitvogel, Laurence [1 ,2 ,3 ,4 ]
Kroemer, Guido [3 ,5 ,6 ,7 ,8 ]
机构：
[1] Inst Gustave Roussy, INSERM, U1015, F-94805 Villejuif, France
[2] Inst Gustave Roussy, Ctr Clin Invest CBT507, Villejuif, France
[3] Inst Gustave Roussy, Villejuif, France
[4] Univ Paris 11, Villejuif, France
[5] INSERM, U848, Villejuif, France
[6] Ctr Rech Cordeliers, Paris, France
[7] Hop Europeen Georges Pompidou, Paris, France
[8] Univ Paris 05, Fac Med, Paris, France
来源：
ONCOIMMUNOLOGY | 2012年 / 1卷 / 08期
关键词：
CELL CARCINOMA PATIENTS; CLINICAL-SIGNIFICANCE; PD-1; PATHWAY; B7-H1; EXPRESSION; MOLECULE; IMMUNOSUPPRESSION; RECEPTORS; LIGAND-1; ANTIBODY;
D O I：
10.4161/onci.21335
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1223 / 1225
页数：3
相关论文
共 50 条
  • [21] Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
    Wu, Bogang
    Sun, Xiujie
    Gupta, Harshita B.
    Yuan, Bin
    Li, Jingwei
    Ge, Fei
    Chiang, Huai-Chin
    Zhang, Xiaowen
    Zhang, Chi
    Zhang, Deyi
    Yang, Jing
    Hu, Yanfen
    Curiel, Tyler J.
    Li, Rong
    ONCOIMMUNOLOGY, 2018, 7 (11):
  • [22] Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
    Cheng, Weishi
    Kang, Kai
    Zhao, Ailin
    Wu, Yijun
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [23] PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
    Ren, Xiaohui
    Wang, Lijuan
    Liu, Likun
    Liu, Juan
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [24] Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
    Zhang, Min
    Liu, Kehai
    Wang, Mingfu
    RSC ADVANCES, 2019, 9 (58) : 33903 - 33911
  • [25] Interplay between inflammasomes and PD-1/PD-L1 and their implications in cancer immunotherapy
    Jiao, Zhongyu
    Zhang, Jun
    CARCINOGENESIS, 2023, 44 (12) : 795 - 808
  • [26] Blocking of the PD-1/PD-L1 interaction by an affinity peptide for cancer immunotherapy
    Luo, H.
    Li, X.
    Zhu, N.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1782 - 1782
  • [27] PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
    Jiang, Yongshuai
    Chen, Ming
    Nie, Hong
    Yuan, Yuanyang
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (05) : 1111 - 1122
  • [28] Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer
    Noguchi, Emi
    Shien, Tadahiko
    Iwata, Hiroji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 321 - 332
  • [29] New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
    Villanueva, Nicolas
    Bazhenova, Lyudmila
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2018, 12
  • [30] Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy
    Hu, Xiaoli
    Wang, Jing
    Chu, Man
    Liu, Yi
    Wang, Zhi-wei
    Zhu, Xueqiong
    MOLECULAR THERAPY, 2021, 29 (03) : 908 - 919
12345